April 2022 - Clever Leaves

Clever Leaves Strengthens Its Presence in the U.S. Through Partnership With Biom Therapeutics

Under the two-year supply agreement Clever Leaves will deliver CBD Isolate to Biom Therapeutics to manufacture a finished product for clinical trials in the United States

Under the two-year supply agreement Clever Leaves will deliver CBD Isolate to Biom Therapeutics to manufacture a finished product for clinical trials in the United States

Clever Leaves to Present at Upcoming April Investor Conferences

BOCA RATON, Fla., April 05, 2022 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, is scheduled to participate in the following investor conferences in April 2022:

Clever Leaves Ready to Export Dried Flower From Colombia

BOCA RATON, Fla., April 04, 2022 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today that after the issuance of Joint Resolution 539 of 2022 by the Colombian Government, it is ready to begin taking advantage of this regulatory framework and expects to export milled cannabis flower by Q3 of 2022 and high THC flower before the end of the year. The Resolution details the process and requirements for exports of medical cannabis flowers and cannabis derivatives and marks the completion of the required regulatory framework.